ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
ABVC Stock Chart & Stats
$2.10
-$0.06(-10.00%)
At close: 4:00 PM EST
$2.10
-$0.06(-10.00%)
Day’s Range― - ―
52-Week Range$0.71 - $5.48
Previous CloseN/A
Volume151.09K
Average Volume (3M)95.05K
Market Cap
$26.97M
Enterprise Value$18.15M
Total Cash (Recent Filing)$745.83K
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding25,440,407
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)4.46
Price to Sales (P/S)62.24
P/FCF Ratio-16.56
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit31.19
Enterprise Value/Ebitda-3.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetA materially stronger balance sheet (debt-to-equity ~0.31 and assets ~$21.1M) reduces near-term refinancing pressure and provides more runway to fund clinical programs or negotiate partnerships. This improves execution flexibility despite ongoing operating losses.
High Gross MarginsNear-100% gross margins indicate very low direct COGS for ABVC’s therapeutic candidates. That suggests attractive product economics post-approval and scalable revenues, meaning future profitability depends more on controlling R&D and SG&A than manufacturing costs.
Proprietary Clinical PipelineA focus on novel, proprietary clinical-stage candidates creates durable upside via IP ownership, potential licensing or partnership deals, and differentiated product positioning. Clinical data can materially re-rate prospects and attract strategic investors or acquirers if programs succeed.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow, with 2025 showing $0, means the company cannot fund development internally. This creates ongoing reliance on external financing, increasing dilution and execution risk and constraining strategic optionality over the medium term.
Deep, Persistent LossesVery large net losses relative to revenue signal high burn and distant profitability. Continued heavy losses erode shareholder equity, limit discretionary investment, and make it harder to secure non-dilutive partnerships without clear clinical progress or milestone events.
Tiny, Volatile Revenue BaseA tiny and erratic revenue base provides no reliable commercial cushion for R&D spending. This undermines forecasting, increases dependency on external capital, and limits evidence of market traction or sustainable operations absent successful clinical or licensing outcomes.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.71 and its highest was $5.48 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $26.97M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 234 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.11.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 25,440,407 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.685%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.40% Mutual Funds
0.05% Other Institutional Investors
97.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---